Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT01124786




Registration number
NCT01124786
Ethics application status
Date submitted
12/05/2010
Date registered
17/05/2010
Date last updated
17/04/2014

Titles & IDs
Public title
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)
Scientific title
A Phase II Randomized, Open-Label, Multicenter Study Comparing CO-1.01 With Gemcitabine as First-Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma
Secondary ID [1] 0 0
CO-101-001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Metastatic Pancreatic Adenocarcinoma 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - CO-1.01
Treatment: Drugs - Gemcitabine

Experimental: CO-1.01 -

Active Comparator: gemcitabine -


Treatment: Drugs: CO-1.01
1250 mg/m2 intravenous infusion weekly for 3 weeks every 4 weeks

Treatment: Drugs: Gemcitabine
1000 mg/m2 intravenous infusion weekly for 7 weeks followed by 1 week rest, then weekly for 3 weeks every 4 weeks
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Overall Survival in Patients With Low High Human Equilibrative Nucleoside Transporter 1 (hENT1) Expression
Timepoint [1] 0 0
Monthly follow up after treatment discontinuation until death, up to 1.5 years.
Secondary outcome [1] 0 0
Overall Survival in All Patients and Patients With hENT1 Expression
Timepoint [1] 0 0
Monthly follow up after treatment discontinuation until death, up to 1.5 years
Secondary outcome [2] 0 0
ORR, Duration of Response, and Progression Free Survival (PFS) in Patients With Measurable/Evaluable Disease, Using RECIST 1.1, up to 1.5 Years
Timepoint [2] 0 0
Every 8 weeks
Secondary outcome [3] 0 0
Cancer Antigen (CA)19-9 Response Rates
Timepoint [3] 0 0
Every 4 weeks, up to 1.5 years
Secondary outcome [4] 0 0
Drug Tolerability and Toxicity
Timepoint [4] 0 0
Every week, up to 1.5 years
Secondary outcome [5] 0 0
Change From Baseline in Pain Severity
Timepoint [5] 0 0
Every 4 weeks, up to 1.5 years
Secondary outcome [6] 0 0
Change From Baseline in Health Status
Timepoint [6] 0 0
Every 4 weeks, up to 1.5 years
Secondary outcome [7] 0 0
Pharmacokinetic (PK) Profile of CO-1.01 Based on Sparse Sampling
Timepoint [7] 0 0
30 days after first dose

Eligibility
Key inclusion criteria
- Metastatic pancreatic ductal adenocarcinoma (i.e., Stage 4).

- Histological/cytological confirmation of metastatic tissue (not primary tumor) by a
central pathology laboratory (H&E stain) to ensure sufficient material is available
for later hENT1 analysis.

- Adjuvant chemotherapy/radiotherapy = 6 months prior to randomization.

- Palliative radiotherapy (if administered) = 1 month prior to randomization.

- CT scan =30 days prior to randomization

- Performance Status (ECOG) 0 or 1.

- Estimated life expectancy = 12 weeks.

- Age = 18 years.

- Adequate hematological and biological function.

- Written consent on an Institutional Review Board/Institutional Ethics
Committee-approved Informed Consent Form prior to any study-specific evaluation.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Prior palliative chemotherapy for pancreatic cancer.

- Radical pancreatic resections (e.g., Whipple procedure) are not allowed < 6 months
prior to randomization. Exploratory laparotomy, palliative (e.g., bypass) surgery, or
other procedures (e.g., stents) are not allowed < 14 days prior to randomization. In
both cases the patient must be sufficiently recovered and stable.

- Symptomatic brain metastases.

- Participation in other investigational drug clinical studies = 30 days prior to
randomization.

- Concomitant treatment with prohibited medications.

- History of allergy to gemcitabine or eggs.

- Presence of any serious or unstable concomitant systemic disorder incompatible with
the clinical study (e.g., substance abuse, uncontrolled intercurrent illness including
active infection, arterial thrombosis, symptomatic pulmonary embolism).

- Any disorder that would hamper protocol compliance.

- Prior nonpancreatic malignancy treated with chemotherapy. Prior malignancies treated
with surgery or radiotherapy alone must be in remission = 3 years. The following prior
malignancies are allowable irrespective of when they occurred: in situ carcinoma of
the cervix, in situ ductal breast cancer, low-grade local bladder cancer, and
nonmelanotic skin cancer.

- Females who are pregnant or breastfeeding.

- Refusal to use adequate contraception for fertile patients (females and males during
the study and for 6 months after the last study treatment). Adequate forms of
contraception are double-barrier methods (condoms or diaphragm with spermicidal jelly
or foam); oral, depot, or injectable contraceptives; intrauterine devices; tubal
ligation.

- Any other reason the investigator considers the patient should not participate in the
study.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/05/2010
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/06/2013
Sample size
Target
Accrual to date
Final
367
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC
Recruitment hospital [1] 0 0
Newcastle Private Hospital - New Lambton Heights
Recruitment hospital [2] 0 0
Port Macquarie Base Hospital - Port Macquarie
Recruitment hospital [3] 0 0
Southern Medical Day Oncology Care Centre - Wollongong
Recruitment hospital [4] 0 0
Flinders Medical Centre - Bedford Park
Recruitment hospital [5] 0 0
Saint Vincent's Hospital - Fitzroy
Recruitment hospital [6] 0 0
Border Medical Oncology, Murray Valley Private Hospital - Wodonga
Recruitment postcode(s) [1] 0 0
2305 - New Lambton Heights
Recruitment postcode(s) [2] 0 0
2444 - Port Macquarie
Recruitment postcode(s) [3] 0 0
2500 - Wollongong
Recruitment postcode(s) [4] 0 0
5042 - Bedford Park
Recruitment postcode(s) [5] 0 0
3065 - Fitzroy
Recruitment postcode(s) [6] 0 0
3690 - Wodonga
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Maryland
Country [6] 0 0
United States of America
State/province [6] 0 0
Minnesota
Country [7] 0 0
United States of America
State/province [7] 0 0
New Jersey
Country [8] 0 0
United States of America
State/province [8] 0 0
New Mexico
Country [9] 0 0
United States of America
State/province [9] 0 0
New York
Country [10] 0 0
United States of America
State/province [10] 0 0
Oregon
Country [11] 0 0
United States of America
State/province [11] 0 0
South Carolina
Country [12] 0 0
United States of America
State/province [12] 0 0
Texas
Country [13] 0 0
United States of America
State/province [13] 0 0
Wisconsin
Country [14] 0 0
Argentina
State/province [14] 0 0
Bahia Blanca
Country [15] 0 0
Argentina
State/province [15] 0 0
Buenos Aires
Country [16] 0 0
Argentina
State/province [16] 0 0
Córdoba
Country [17] 0 0
Argentina
State/province [17] 0 0
Santa Fe
Country [18] 0 0
Belgium
State/province [18] 0 0
Antwerpen
Country [19] 0 0
Belgium
State/province [19] 0 0
Brussels
Country [20] 0 0
Belgium
State/province [20] 0 0
Haine-Saint-Paul
Country [21] 0 0
Brazil
State/province [21] 0 0
Distrito Federal
Country [22] 0 0
Brazil
State/province [22] 0 0
Minas Gerais
Country [23] 0 0
Brazil
State/province [23] 0 0
Rio Grande do Sul
Country [24] 0 0
Brazil
State/province [24] 0 0
Rio Grande Do Sul
Country [25] 0 0
Brazil
State/province [25] 0 0
Santa Catarina
Country [26] 0 0
Brazil
State/province [26] 0 0
Sao Paulo
Country [27] 0 0
Brazil
State/province [27] 0 0
Rio de Janeiro
Country [28] 0 0
Canada
State/province [28] 0 0
Alberta
Country [29] 0 0
France
State/province [29] 0 0
Bayonne Cedex
Country [30] 0 0
France
State/province [30] 0 0
Bordeaux
Country [31] 0 0
France
State/province [31] 0 0
Limoges Cedex
Country [32] 0 0
France
State/province [32] 0 0
Montpellier Cedex 5
Country [33] 0 0
France
State/province [33] 0 0
Montpellier
Country [34] 0 0
France
State/province [34] 0 0
Saint Herblain cedex
Country [35] 0 0
France
State/province [35] 0 0
Villejuif Cedex
Country [36] 0 0
Germany
State/province [36] 0 0
Bayern
Country [37] 0 0
Germany
State/province [37] 0 0
Mecklenburg-Vorpommern
Country [38] 0 0
Germany
State/province [38] 0 0
Nordrhein-Westfalen
Country [39] 0 0
Germany
State/province [39] 0 0
Thueringen
Country [40] 0 0
Germany
State/province [40] 0 0
Berlin
Country [41] 0 0
Germany
State/province [41] 0 0
Dresden
Country [42] 0 0
Germany
State/province [42] 0 0
Magdeburg
Country [43] 0 0
Germany
State/province [43] 0 0
Ulm
Country [44] 0 0
Italy
State/province [44] 0 0
Emilia-Romagna
Country [45] 0 0
Italy
State/province [45] 0 0
Milano
Country [46] 0 0
Italy
State/province [46] 0 0
Padova
Country [47] 0 0
Italy
State/province [47] 0 0
Torrette di Ancona
Country [48] 0 0
Italy
State/province [48] 0 0
Verona
Country [49] 0 0
Netherlands
State/province [49] 0 0
Noord-Holland
Country [50] 0 0
Norway
State/province [50] 0 0
Kristiansand
Country [51] 0 0
Norway
State/province [51] 0 0
Oslo
Country [52] 0 0
Russian Federation
State/province [52] 0 0
Republic of Udmurtia
Country [53] 0 0
Russian Federation
State/province [53] 0 0
Ekaterinburg
Country [54] 0 0
Russian Federation
State/province [54] 0 0
Irkutsk
Country [55] 0 0
Russian Federation
State/province [55] 0 0
Krasnodar
Country [56] 0 0
Russian Federation
State/province [56] 0 0
Kursk
Country [57] 0 0
Russian Federation
State/province [57] 0 0
Moscow
Country [58] 0 0
Russian Federation
State/province [58] 0 0
Novosibirsk
Country [59] 0 0
Russian Federation
State/province [59] 0 0
St. Petersburg
Country [60] 0 0
Russian Federation
State/province [60] 0 0
Tambov
Country [61] 0 0
Russian Federation
State/province [61] 0 0
Tula
Country [62] 0 0
Russian Federation
State/province [62] 0 0
Yaroslavl
Country [63] 0 0
Sweden
State/province [63] 0 0
Jonkoping
Country [64] 0 0
Sweden
State/province [64] 0 0
Linköping
Country [65] 0 0
Sweden
State/province [65] 0 0
Växjö
Country [66] 0 0
Ukraine
State/province [66] 0 0
Dnipropetrovsk
Country [67] 0 0
Ukraine
State/province [67] 0 0
Donetsk
Country [68] 0 0
Ukraine
State/province [68] 0 0
Kharkiv
Country [69] 0 0
Ukraine
State/province [69] 0 0
Kiev
Country [70] 0 0
Ukraine
State/province [70] 0 0
Lviv
Country [71] 0 0
Ukraine
State/province [71] 0 0
Mykolayiv
Country [72] 0 0
Ukraine
State/province [72] 0 0
Uzhorod
Country [73] 0 0
Ukraine
State/province [73] 0 0
Zaporizhya
Country [74] 0 0
United Kingdom
State/province [74] 0 0
England
Country [75] 0 0
United Kingdom
State/province [75] 0 0
Scotland

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Clovis Oncology, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to determine whether CO-1.01 is safe and effective in the
treatment of patients with metastatic pancreatic cancer and low hENT1 expression compared
with gemcitabine.
Trial website
https://clinicaltrials.gov/ct2/show/NCT01124786
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT01124786